The People Behind The Process: How Resilience's Teams Enable Flexible Biopharma Manufacturing

Cell and gene therapies sit at one end of the demand curve, while GLP-1s, vaccines, and biosimilars sit at the other. Sponsors working across that range, often against a launch window or a funding milestone, increasingly expect manufacturing partners to say yes to compressed timelines.

Two Resilience site leaders weigh in: Kyle Kissick, MSAT lead in Cincinnati, and Nick Van-Gemert, senior manager of manufacturing in Toronto. They explain why flexibility means something different for a large pharma sponsor than for an emerging biotech, and how equipment strategy and automation support it. One example describes a drug delivery, device assembly, and packaging platform stood up in under 18 months.

Read on to see what separates flexible operations from rigid ones.